

\$ in millions, except for per-share amounts

All Data as of: 7/26/2019

Diversified Pharmaceuticals

| Company | Ticker | Share Price | Shares Out | Equity Value | Net Debt (Cash) | Enterprise Value | LTM | | | | Margin Analysis | | | Enterprise Value/ | | |
|---------------------|------------------------------|-------------|------------|--------------|-----------------|------------------|------------|------------|------------|--------|-----------------|--------|-------|-------------------|--------|--------|
| | | | | | | | Sales | EBITDA | EBIT | EPS | Gross Profit | EBITDA | EBIT | Sales | EBITDA | EBIT |
| Pfizer Inc. | NYSE:PFE | \$43.11 | 5,551.8 | \$239,310.5 | \$34,919.0 | \$274,229.5 | \$53,859.0 | \$22,369.0 | \$16,053.0 | \$1.66 | 79.6% | 41.5% | 29.8% | 5.1 x | 12.3 x | 17.1 x |
| GlaxoSmithKline plc | LSE:GSK | 20.88 | 4,948.0 | 103,320.1 | 37,173.6 | 140,493.7 | 40,358.1 | 13,587.0 | 9,899.2 | 1.02 | 68.5% | 33.7% | 24.5% | 3.5 x | 10.3 x | 14.2 x |
| Johnson & Johnson | NYSE:JNJ | 130.82 | 2,655.1 | 347,334.4 | 14,939.0 | 362,273.4 | 81,325.0 | 27,896.0 | 20,908.0 | 4.81 | 66.8% | 34.3% | 25.7% | 4.8 x | 13.0 x | NM |
| Merck & Co., Inc. | NYSE:MRK | 81.31 | 2,574.6 | 209,344.3 | 18,171.0 | 227,515.3 | 43,073.0 | 16,095.0 | 11,850.0 | 2.18 | 69.1% | 37.4% | 27.5% | 5.3 x | 14.1 x | 19.2 x |
| Novartis AG | SWX:NOVN | 93.07 | 2,291.8 | 213,300.7 | 20,025.0 | 233,325.7 | 53,829.0 | 16,899.0 | 11,723.0 | 4.30 | 69.2% | 31.4% | 21.8% | 4.3 x | 13.8 x | 19.9 x |
| AstraZeneca PLC | LSE:AZN | 85.53 | 1,311.8 | 112,195.3 | 13,470.0 | 125,665.3 | 23,071.0 | 4,492.0 | 1,751.0 | 0.28 | 80.3% | 19.5% | 7.6% | 5.4 x | 28.0 x | 71.8 x |
| | Median | \$83.4 | \$2,614.9 | \$211,322.5 | \$19,098.0 | \$230,420.5 | \$48,451.0 | \$16,497.0 | \$11,786.5 | \$1.92 | 72.2% | 33.0% | 22.8% | 4.8 x | 13.4 x | 19.2 x |
| | Increase from Week Prior | \$2.8 | \$0.0 | (\$1,588.9) | \$0.0 | (\$1,588.9) | \$0.0 | \$0.0 | \$0.0 | \$0.0 | 0.0% | 0.0% | 0.0% | -0.1 x | -0.1 x | 0.0 x |
| | Increase from Year to Date | \$23.0 | (\$165.4) | \$37,904.7 | \$4,771.6 | \$42,625.2 | \$4,276.5 | \$1,964.0 | \$2,966.5 | \$0.2 | 1.6% | 0.0% | 0.0% | 0.8 x | 0.3 x | -1.6 x |
| | Increase from Year over Year | \$13.3 | (\$71.4) | \$28,016.5 | \$1,441.5 | \$29,478.5 | \$3,485.5 | \$3,523.0 | \$2,424.5 | \$0.2 | 0.5% | 0.0% | 0.0% | 0.2 x | -0.8 x | -1.0 x |

Specialty Pharmaceuticals

| Company | Ticker | Share Price | Shares Out | Equity Value | Net Debt (Cash) | Enterprise Value | LTM | | | | Margin Analysis | | | Enterprise Value/ | | |
|---------------------------------------|------------------------------|-------------|------------|--------------|-----------------|------------------|-----------|-----------|-----------|----------|-----------------|--------|-------|-------------------|----------|---------|
| | | | | | | | Sales | EBITDA | EBIT | EPS | Gross Profit | EBITDA | EBIT | Sales | EBITDA | EBIT |
| UCB SA | ENXTBR:UCB | \$79.62 | 188.9 | \$15,040.4 | \$0.0 | \$15,040.4 | \$5,332.3 | \$1,500.9 | \$1,167.5 | \$3.73 | 73.9% | 28.1% | 21.9% | 2.8 x | 10.0 x | 12.9 x |
| ADVANZ PHARMA Corp. | TSX:ADVZ | 13.87 | 48.9 | 678.4 | 1,105.3 | 1,783.7 | 520.4 | 240.9 | 0.9 | (12.14) | 67.5% | 46.3% | 3.4 x | 7.4 x | 1897.5 x | |
| Takeda Pharmaceutical Company Limited | TSE:TAK | 33.84 | 1,566.1 | 53,004.2 | 46,972.2 | 99,976.5 | 18,926.3 | 4,750.4 | 2,416.0 | 0.95 | 72.4% | 25.1% | 12.8% | 5.3 x | 21.0 x | NM |
| H. Lundbeck A/S | CPSE:LUN | 38.80 | 198.8 | 7,712.7 | (677.6) | 7,035.1 | 2,671.0 | 911.8 | 742.3 | 2.58 | 80.6% | 34.1% | 27.8% | 2.6 x | 7.7 x | 9.5 x |
| Allergan plc | NYSE:AGN | 161.02 | 327.8 | 52,786.2 | 22,273.5 | 75,059.7 | 15,712.4 | 7,062.2 | 624.6 | (0.98) | 85.8% | 44.9% | 4.0% | 4.8 x | 10.6 x | 120.2 x |
| Bausch Health Companies Inc. | NYSE:BHC | 23.74 | 351.9 | 8,353.7 | 23,692.0 | 32,045.7 | 8,401.0 | 3,354.0 | 789.0 | (2.06) | 72.4% | 39.9% | 9.4% | 3.8 x | 9.6 x | 40.6 x |
| | Median | \$36.3 | \$263.3 | \$11,697.1 | \$11,689.4 | \$23,543.1 | \$6,866.6 | \$2,427.5 | \$765.6 | (\$0.01) | 75.4% | 36.4% | 12.7% | 3.6 x | 9.8 x | 40.6 x |
| | Increase from Week Prior | \$0.0 | \$0.0 | (\$82.2) | \$0.0 | (\$82.2) | \$0.0 | \$0.0 | \$0.0 | \$0.0 | 0.0% | 0.0% | 0.0% | 0.0 x | -0.1 x | 0.2 x |
| | Increase from Year to Date | (\$59.7) | (\$6.9) | (\$14,271.4) | \$9,402.8 | (\$6,123.1) | (\$499.2) | \$593.3 | \$365.7 | (\$1.2) | -0.6% | -0.1% | -0.1% | -1.7 x | -10.9 x | 10.3 x |
| | Increase from Year over Year | (\$26.6) | (\$5.6) | (\$3,407.2) | \$6,579.2 | (\$849.5) | (\$51.2) | (\$47.1) | \$212.4 | \$0.3 | 0.5% | 0.0% | 0.0% | -0.7 x | -2.0 x | -5.1 x |

Generic Pharmaceuticals

| Company | Ticker | Share Price | Shares Out | Equity Value | Net Debt (Cash) | Enterprise Value | LTM | | | | Margin Analysis | | | Enterprise Value/ | | |
|--|------------------------------|-------------|------------|--------------|-----------------|------------------|------------|-----------|-----------|---------|-----------------|--------|--------|-------------------|--------|--------|
| | | | | | | | Sales | EBITDA | EBIT | EPS | Gross Profit | EBITDA | EBIT | Sales | EBITDA | EBIT |
| Teva Pharmaceutical Industries Limited | NYSE:TEVA | \$7.54 | 1,092.5 | \$8,237.2 | \$27,189.0 | \$35,426.2 | \$18,084.0 | \$4,464.0 | \$2,686.0 | \$1.52 | 43.3% | 24.7% | 14.9% | 2.0 x | 7.9 x | 13.2 x |
| Mylan N.V. | NasdaqGS:MYL | 18.60 | 515.5 | 9,585.1 | 13,673.9 | 23,259.0 | 11,244.9 | 3,541.2 | 1,652.8 | 1.37 | 39.8% | 31.5% | 14.7% | 2.1 x | 6.6 x | 14.1 x |
| Lupin Limited | BSE:500257 | 11.28 | 452.6 | 5,104.3 | 774.4 | 5,878.7 | 2,413.0 | 413.9 | 259.5 | 0.36 | 62.8% | 17.2% | 10.8% | 2.4 x | 14.2 x | 27.7 x |
| Hikma Pharmaceuticals PLC | LSE:HIK | 22.74 | 242.2 | 5,508.6 | 340.0 | 5,848.6 | 2,070.0 | 528.0 | 429.0 | 0.95 | 48.5% | 25.5% | 20.7% | 2.8 x | 11.1 x | 13.6 x |
| Dr. Reddy's Laboratories Limited | BSE:500124 | 39.25 | 165.8 | 6,509.4 | 167.6 | 6,677.1 | 2,225.7 | 465.3 | 301.5 | 1.20 | 68.9% | 20.9% | 13.5% | 3.0 x | 14.3 x | 22.1 x |
| Perrigo Company plc | NYSE:PRGO | 53.56 | 136.0 | 7,283.7 | 2,527.4 | 9,811.1 | 4,689.2 | 837.5 | 426.8 | 1.55 | 38.1% | 17.9% | 9.1% | 2.1 x | 11.7 x | 23.0 x |
| | Median | \$20.7 | \$347.4 | \$6,896.6 | \$1,650.9 | \$8,244.1 | \$3,551.1 | \$682.8 | \$427.9 | \$1.29 | 50.2% | 13.9% | 22.9% | 2.3 x | 11.4 x | 18.1 x |
| | Increase from Week Prior | \$0.3 | \$0.0 | \$244.2 | \$0.0 | \$244.2 | \$0.0 | \$0.0 | \$0.0 | \$0.0 | 0.0% | 0.0% | 0.0% | 0.1 x | 0.2 x | 4.2 x |
| | Increase from Year to Date | (\$29.8) | \$22.5 | (\$9,980.7) | \$88.4 | (\$11,433.8) | (\$133.0) | (\$154.5) | (\$171.2) | (\$0.4) | -3.3% | -0.1% | -1.9 x | -2.7 x | 0.5 x | 0.5 x |
| | Increase from Year over Year | (\$6.7) | \$0.6 | (\$1,146.1) | (\$120.6) | (\$1,570.1) | (\$60.1) | (\$92.0) | (\$68.5) | \$0.1 | 1.9% | 0.0% | 0.0% | -0.4 x | -0.6 x | -2.7 x |

Nutraceuticals

| Company | Ticker | Share Price | Shares Out | Equity Value | Net Debt (Cash) | Enterprise Value | LTM | | | | Margin Analysis | | | Enterprise Value/ | | |
|----------------------------------|------------------------------|-------------|------------|--------------|-----------------|------------------|-----------|---------|---------|--------|-----------------|--------|-------|-------------------|--------|--------|
| | | | | | | | Sales | EBITDA | EBIT | EPS | Gross Profit | EBITDA | EBIT | Sales | EBITDA | EBIT |
| Herbalife Nutrition Ltd. | NYSE:HLF | \$41.39 | 141.2 | \$5,841.5 | \$1,439.2 | \$7,280.7 | \$4,887.1 | \$783.5 | \$684.3 | \$2.32 | 52.8% | 16.0% | 14.0% | 1.5 x | 9.3 x | 10.6 x |
| LifeVantage Corporation | NasdaqCM:LFVN | 11.19 | 14.3 | 160.5 | (14.0) | 146.5 | 223.8 | 10.2 | 8.4 | 0.43 | 83.8% | 4.6% | 3.8% | 0.7 x | 14.4 x | 17.3 x |
| Medfast, Inc. | NYSE:MED | 114.87 | 11.9 | 1,366.7 | (106.9) | 1,259.8 | 568.3 | 83.1 | 79.1 | 3.69 | 75.7% | 14.6% | 13.9% | 2.2 x | 15.2 x | 15.9 x |
| Nature's Sunshine Products, Inc. | NasdaqCM:NATR | 8.94 | 19.3 | 172.3 | (21.0) | 151.3 | 368.7 | 21.1 | 11.4 | 0.20 | 73.9% | 5.7% | 3.1% | 0.4 x | 7.2 x | 13.2 x |
| USANA Health Sciences, Inc. | NYSE:USNA | 66.66 | 23.3 | 1,555.8 | (234.4) | 1,321.4 | 1,124.8 | 175.5 | 159.6 | 4.95 | 82.8% | 15.6% | 14.2% | 1.2 x | 7.5 x | 8.3 x |
| | Median | \$41.4 | \$19.3 | \$1,366.7 | (\$21.0) | \$1,259.8 | \$568.3 | \$83.1 | \$79.1 | \$2.32 | 73.8% | 11.3% | 9.8% | 1.2 x | 9.3 x | 13.2 x |
| | Increase from Week Prior | \$0.4 | \$0.0 | \$13.4 | \$0.0 | \$13.4 | \$0.0 | \$0.0 | \$0.0 | \$0.0 | 0.0% | 0.0% | 0.0% | 0.1 x | 0.1 x | -0.2 x |
| | Increase from Year to Date | \$14.6 | \$0.7 | \$1,009.5 | \$19.5 | \$969.5 | \$243.6 | \$45.2 | \$48.3 | \$0.7 | 0.3% | 0.0% | 0.0% | 0.1 x | 0.9 x | 3.5 x |
| | Increase from Year over Year | (\$11.6) | \$0.2 | (\$759.9) | \$17.7 | (\$763.5) | \$197.2 | \$26.8 | \$27.6 | \$0.5 | 0.3% | 0.0% | 0.0% | -0.9 x | -4.1 x | -4.6 x |

Biotechnology

| Company | Ticker | Share Price | Shares Out | Equity Value | Net Debt (Cash) | Enterprise Value | LTM | | | | Margin Analysis | | | Enterprise Value/ | | |
|-----------------------|------------------------------|-------------|------------|--------------|-----------------|------------------|------------|------------|------------|---------|-----------------|--------|-------|-------------------|--------|---------|
| | | | | | | | Sales | EBITDA | EBIT | EPS | Gross Profit | EBITDA | EBIT | Sales | EBITDA | EBIT |
| Amgen Inc. | NasdaqGS:AMGN | \$174.19 | 609.9 | \$106,244.7 | \$7,211.0 | \$113,455.7 | \$23,750.0 | \$12,267.0 | \$10,297.0 | \$9.57 | 82.3% | 51.7% | 43.4% | 4.8 x | 9.2 x | 11.0 x |
| Gilead Sciences, Inc. | NasdaqGS:GILD | 66.73 | 1,271.6 | 84,850.8 | (1,927.0) | 82,923.8 | 22,320.0 | 10,535.0 | 9,104.0 | 4.09 | 78.5% | 47.2% | 40.8% | 3.7 x | 7.9 x | 9.1 x |
| Biogen Inc. | NasdaqGS:BIIB | 237.76 | 184.4 | 43,854.2 | 3,327.4 | 47,181.6 | 14,071.8 | 7,696.5 | 7,148.3 | 18.91 | 81.6% | 54.7% | 50.8% | 3.4 x | 6.1 x | NM |
| CSL Limited | ASX:CSL | 156.52 | 453.1 | 70,925.9 | 3,979.8 | 74,905.7 | 8,273.5 | 2,735.4 | 2,457.3 | 3.15 | 56.2% | 33.1% | 29.7% | 5.1 x | 27.4 x | 30.5 x |
| Celgene Corporation | NasdaqGS:CELG | 92.75 | 705.3 | 65,412.8 | 12,897.0 | 78,309.8 | 15,768.0 | 6,693.0 | 7,027.0 | 4.20 | 92.4% | 48.8% | 44.6% | 9.0 x | 10.2 x | 11.1 x |
| Novo Nordisk A/S | CPSE:NOVO B | 48.80 | 2,371.2 | 115,714.7 | (712.2) | 115,002.6 | 17,168.2 | 7,994.4 | 7,372.8 | 1.88 | 84.1% | 46.6% | 42.9% | NM | 14.4 x | 15.6 x |
| | Median | \$124.6 | \$657.6 | \$77,888.4 | \$3,653.6 | \$80,616.8 | \$16,468.1 | \$7,845.5 | \$7,260.5 | \$4.15 | 79.8% | 47.0% | 42.0% | 4.8 x | 9.7 x | 11.1 x |
| | Increase from Week Prior | \$0.3 | \$0.0 | \$649.7 | \$0.0 | \$1,973.7 | \$0.0 | \$0.0 | \$0.0 | \$0.0 | 0.0% | 0.0% | 0.0% | -0.1 x | 0.0 x | -0.1 x |
| | Increase from Year to Date | \$14.2 | (\$112.4) | (\$30,381.7) | \$1,113.6 | (\$31,466.5) | \$3,232.8 | \$1,430.2 | \$1,360.8 | (\$0.4) | 1.2% | 0.0% | 0.0% | -1.6 x | -6.7 x | -10.3 x |
| | Increase from Year over Year | \$7.3 | (\$24.9) | (\$7,482.0) | \$516.5 | (\$11,001.3) | \$877.9 | \$612.5 | \$430.0 | (\$1.1) | 0.3% | 0.0% | 0.0% | -0.9 x | -3.6 x | -3.6 x |

\$ in millions, except for per-share amounts

All Data as of: 7/26/2019

Medical Devices

| Company | Ticker | Share Price | Shares Out | Equity Value | Net Debt (Cash) | Enterprise Value | LTM | | | | Margin Analysis | | | Enterprise Value/ | | |
|----------------------------------|----------|-------------|------------|--------------|-----------------|------------------|------------|-----------|-----------|--------|-----------------|--------|-------|-------------------|--------|--------|
| | | | | | | | Sales | EBITDA | EBIT | EPS | Gross Profit | EBITDA | EBIT | Sales | EBITDA | EBIT |
| Boston Scientific Corporation | NYSE:BSX | \$42.09 | 1,390.7 | \$58,532.6 | \$9,355.0 | \$67,887.6 | \$10,077.0 | \$2,691.0 | \$1,764.0 | \$0.67 | 71.2% | 26.7% | 17.5% | 6.7 x | 25.2 x | 38.5 x |
| Medtronic plc | NYSE:MDT | 102.62 | 1,341.2 | 137,629.5 | 15,470.0 | 153,099.5 | 30,557.0 | 9,234.0 | 6,575.0 | 2.65 | 70.3% | 30.2% | 21.5% | 5.0 x | 16.6 x | 23.3 x |
| Becton, Dickinson and Company | NYSE:BDX | 254.93 | 269.7 | 68,762.8 | 19,917.0 | 88,679.8 | 17,036.0 | 5,020.0 | 2,760.0 | 5.24 | 47.9% | 16.2% | 29.5% | 5.2 x | 17.7 x | 32.1 x |
| Edwards Lifesciences Corporation | NYSE:EW | 212.60 | 208.5 | 44,327.4 | (266.0) | 44,061.4 | 3,964.2 | 1,214.4 | 1,134.1 | 3.23 | 74.9% | 30.6% | 28.6% | 11.1 x | 36.3 x | 38.9 x |
| Smith & Nephew plc | LSE:SN | 22.25 | 873.1 | 19,427.6 | 1,103.0 | 20,530.6 | 4,904.0 | 1,353.0 | 969.0 | 0.64 | 73.5% | 27.6% | 19.8% | 4.2 x | 15.2 x | 21.2 x |
| Median | | \$102.6 | \$873.1 | \$58,532.6 | \$9,355.0 | \$67,887.6 | \$10,077.0 | \$2,691.0 | \$1,764.0 | \$2.65 | 67.6% | 28.9% | 20.7% | 5.2 x | 17.7 x | 32.1 x |
| Increase from Week Prior | | \$1.8 | \$0.0 | (\$222.5) | \$0.0 | (\$222.5) | \$0.0 | \$0.0 | \$0.0 | \$0.0 | 0.0% | 0.0% | 0.0% | 0.1 x | 0.2 x | 0.4 x |
| Increase from Year to Date | | \$25.7 | (\$22.8) | \$33,727.2 | \$3,997.0 | \$37,724.2 | \$2,600.0 | \$842.0 | \$681.0 | \$0.8 | -0.3% | 0.0% | 0.0% | 1.2 x | 1.4 x | 8.4 x |
| Increase from Year over Year | | \$13.4 | \$0.1 | \$11,163.7 | \$3,070.0 | \$14,233.7 | \$578.0 | \$129.0 | \$59.0 | \$0.0 | 0.2% | 0.0% | 0.0% | -0.4 x | -2.9 x | 0.7 x |

Healthcare Facilities

| Company | Ticker | Share Price | Shares Out | Equity Value | Net Debt (Cash) | Enterprise Value | LTM | | | | Margin Analysis | | | Enterprise Value/ | | |
|---------------------------------|----------|-------------|------------|--------------|-----------------|------------------|-------------|-----------|-----------|--------|-----------------|--------|-------|-------------------|--------|--------|
| | | | | | | | Sales | EBITDA | EBIT | EPS | Gross Profit | EBITDA | EBIT | Sales | EBITDA | EBIT |
| HCA Healthcare, Inc. | NYSE:HCA | \$144.59 | 342.3 | \$49,494.2 | \$35,998.0 | \$85,492.2 | \$47,771.0 | \$9,341.0 | \$6,997.0 | \$7.11 | 38.0% | 19.6% | 14.6% | 1.8 x | 9.2 x | 12.2 x |
| Universal Health Services, Inc. | NYSE:UHS | 151.06 | 90.1 | 13,616.5 | 4,419.8 | 18,036.3 | 11,063.0 | 1,727.9 | 1,256.3 | 7.05 | 40.4% | 15.6% | 11.4% | 1.6 x | 10.4 x | 14.4 x |
| Tenet Healthcare Corporation | NYSE:THC | 21.76 | 103.1 | 2,244.1 | 15,580.0 | 17,824.1 | 18,159.0 | 2,729.0 | 1,923.0 | 3.54 | 36.4% | 15.0% | 10.6% | 1.0 x | 6.5 x | 9.3 x |
| Quorum Health Corporation | NYSE:QHC | 1.65 | 31.2 | 51.6 | 1,284.7 | 1,336.2 | 1,834.6 | 96.6 | 42.1 | (2.09) | 37.2% | 5.3% | 2.3% | 0.7 x | 13.8 x | 31.7 x |
| Community Health Systems, Inc. | NYSE:CYH | 2.12 | 113.8 | 241.3 | 13,953.0 | 14,194.3 | 13,842.0 | 1,418.0 | 880.0 | (1.09) | 38.1% | 10.2% | 6.4% | 1.0 x | 10.0 x | 16.1 x |
| Median | | \$21.8 | \$103.1 | \$2,244.1 | \$13,953.0 | \$17,824.1 | \$13,842.0 | \$1,727.9 | \$1,256.3 | \$3.54 | 38.0% | 13.1% | 9.0% | 1.0 x | 10.0 x | 14.4 x |
| Increase from Week Prior | | \$3.7 | \$0.0 | \$379.5 | \$0.0 | \$1,449.1 | \$0.0 | \$0.0 | \$0.0 | \$0.0 | 0.0% | 0.0% | 0.0% | 0.0 x | 0.5 x | 1.3 x |
| Increase from Year to Date | | (\$8.5) | \$3.5 | (\$891.4) | (\$201.0) | \$650.2 | (\$4,792.0) | (\$470.1) | (\$144.7) | \$1.6 | -0.8% | 0.0% | 0.0% | 0.0 x | 2.2 x | 2.1 x |
| Increase from Year over Year | | (\$17.1) | \$1.1 | (\$1,723.6) | \$446.0 | \$2,125.3 | (\$133.0) | \$26.8 | \$2.0 | \$2.5 | 1.0% | 0.0% | 0.0% | 0.0 x | 0.8 x | 1.8 x |

Managed Care

| Company | Ticker | Share Price | Shares Out | Equity Value | Net Debt (Cash) | Enterprise Value | LTM | | | | Margin Analysis | | | Enterprise Value/ | | |
|---------------------------------|-----------|-------------|------------|--------------|-----------------|------------------|-------------|------------|------------|---------|-----------------|--------|------|-------------------|--------|--------|
| | | | | | | | Sales | EBITDA | EBIT | EPS | Gross Profit | EBITDA | EBIT | Sales | EBITDA | EBIT |
| UnitedHealth Group Incorporated | NYSE:UNH | \$251.86 | 950.3 | \$239,353.4 | \$28,528.0 | \$267,881.4 | \$235,876.0 | \$20,598.0 | \$18,663.0 | \$9.94 | 23.5% | 8.7% | 7.9% | 1.1 x | 13.0 x | 14.4 x |
| Anthem, Inc. | NYSE:ANTM | 298.17 | 255.8 | 76,277.0 | 16,481.0 | 92,758.0 | 96,742.0 | 6,483.0 | 5,908.0 | 12.30 | 20.6% | 6.7% | 6.1% | 1.0 x | 14.3 x | 15.7 x |
| Humana Inc. | NYSE:HUM | 276.06 | 135.0 | 37,277.8 | 2,821.0 | 40,098.8 | 58,740.0 | 3,420.0 | 3,187.0 | 13.06 | 18.8% | 5.8% | 5.4% | 0.7 x | 11.7 x | 12.6 x |
| Cigna Corporation | NYSE:C | 166.92 | 379.5 | 63,339.1 | 36,194.0 | 99,533.1 | 75,145.0 | 6,983.0 | 5,870.0 | 11.57 | 24.6% | 9.3% | 7.8% | 1.3 x | 14.3 x | 17.0 x |
| Centene Corporation | NYSE:CNC | 53.03 | 413.6 | 21,931.4 | 1,027.0 | 22,958.4 | 65,491.0 | 3,137.0 | 2,540.0 | 1.88 | 17.7% | 4.8% | 3.9% | 0.4 x | 7.3 x | 9.0 x |
| Median | | \$251.9 | \$379.5 | \$63,339.1 | \$16,481.0 | \$92,758.0 | \$75,145.0 | \$6,483.0 | \$5,870.0 | \$11.57 | 21.0% | 7.1% | 6.2% | 1.0 x | 13.0 x | 14.4 x |
| Increase from Week Prior | | (\$4.8) | \$0.0 | (\$1,568.9) | \$0.0 | (\$1,427.0) | \$0.0 | \$0.0 | \$0.0 | \$0.0 | 0.0% | 0.0% | 0.0% | 0.0 x | -0.2 x | -0.2 x |
| Increase from Year to Date | | \$112.4 | \$121.9 | \$26,935.5 | \$13,280.0 | \$51,862.4 | \$20,856.0 | \$2,459.0 | \$2,148.0 | \$3.0 | -2.3% | 0.0% | 0.0% | 0.3 x | 2.8 x | 3.4 x |
| Increase from Year over Year | | \$4.8 | \$119.5 | \$19,403.3 | \$14,811.0 | \$47,786.7 | \$20,136.0 | \$1,572.0 | \$1,199.0 | \$1.4 | -2.4% | 0.0% | 0.0% | 0.1 x | 1.0 x | 0.2 x |

Healthcare Services

| Company | Ticker | Share Price | Shares Out | Equity Value | Net Debt (Cash) | Enterprise Value | LTM | | | | Margin Analysis | | | Enterprise Value/ | | |
|--|-----------|-------------|------------|--------------|-----------------|------------------|------------|-----------|-----------|---------|-----------------|--------|-------|-------------------|--------|--------|
| | | | | | | | Sales | EBITDA | EBIT | EPS | Gross Profit | EBITDA | EBIT | Sales | EBITDA | EBIT |
| Laboratory Corporation of America Holdings | NYSE:LH | \$165.80 | 98.5 | \$16,331.3 | \$7,314.2 | \$23,645.5 | \$11,291.7 | \$1,890.1 | \$1,437.2 | \$7.48 | 28.1% | 16.7% | 12.7% | 2.1 x | 12.5 x | 16.5 x |
| Charles River Laboratories International, Inc. | NYSE:CRIL | 140.03 | 48.8 | 6,826.8 | 1,572.2 | 8,399.1 | 2,376.7 | 539.0 | 365.1 | 3.97 | 36.7% | 22.7% | 15.4% | 3.5 x | 15.6 x | 23.0 x |
| Cigna Corporation | NYSE:C | 166.92 | 379.5 | 63,339.1 | 36,194.0 | 99,533.1 | 75,145.0 | 6,983.0 | 5,870.0 | 11.57 | 24.6% | 9.3% | 7.8% | 1.3 x | 14.3 x | 17.0 x |
| STERIS plc | NYSE:STE | 148.97 | 84.6 | 12,595.8 | 962.6 | 13,558.3 | 2,782.2 | 687.1 | 477.3 | 3.23 | 42.6% | 24.7% | 17.2% | 4.9 x | 19.7 x | 28.4 x |
| Quest Diagnostics Incorporated | NYSE:DGX | 101.23 | 134.7 | 13,632.6 | 4,299.0 | 17,931.6 | 7,572.0 | 1,481.0 | 1,158.0 | 4.65 | 35.2% | 19.6% | 15.3% | 2.4 x | 12.1 x | 15.5 x |
| Median | | \$149.0 | \$98.5 | \$13,632.6 | \$4,299.0 | \$17,931.6 | \$7,572.0 | \$1,481.0 | \$1,158.0 | \$4.65 | 33.4% | 18.6% | 13.7% | 2.4 x | 14.3 x | 17.0 x |
| Increase from Week Prior | | \$2.7 | \$0.0 | \$291.9 | \$0.0 | \$291.9 | \$0.0 | \$0.0 | \$0.0 | \$0.0 | 0.0% | 0.0% | 0.0% | -0.4 x | -0.4 x | -0.4 x |
| Increase from Year to Date | | \$68.6 | (\$2.7) | \$3,434.7 | \$1,098.0 | \$4,209.7 | \$79.0 | (\$27.0) | (\$46.0) | \$0.3 | -3.8% | 0.0% | 0.0% | 0.2 x | 3.3 x | 2.6 x |
| Increase from Year over Year | | \$24.3 | (\$3.8) | (\$1,037.2) | \$2,629.0 | (\$440.2) | \$48.0 | (\$101.0) | (\$131.0) | (\$0.3) | -2.5% | 0.0% | 0.0% | -0.1 x | 2.0 x | 0.8 x |

Healthcare Technology

| Company | Ticker | Share Price | Shares Out | Equity Value | Net Debt (Cash) | Enterprise Value | LTM | | | | Margin Analysis | | | Enterprise Value/ | | |
|---------------------------------------|---------------|-------------|------------|--------------|-----------------|------------------|--------------|-------------|-------------|---------|-----------------|--------|-------|-------------------|---------|---------|
| | | | | | | | Sales | EBITDA | EBIT | EPS | Gross Profit | EBITDA | EBIT | Sales | EBITDA | EBIT |
| Cerner Corporation | NasdaqGS:CERN | \$73.38 | 325.4 | \$23,879.4 | \$226.6 | \$24,106.0 | \$5,526.7 | \$1,203.4 | \$757.3 | \$1.52 | 82.1% | 21.8% | 13.7% | 4.4 x | 20.0 x | 31.8 x |
| Omnicell, Inc. | NasdaqGS:OMCL | 75.68 | 41.2 | 3,119.4 | 44.3 | 3,163.7 | 835.9 | 107.8 | 67.9 | 0.53 | 48.1% | 12.9% | 8.1% | 3.8 x | 29.3 x | 46.6 x |
| Allscripts Healthcare Solutions, Inc. | NasdaqGS:MDRX | 10.62 | 166.4 | 1,766.7 | 769.1 | 2,535.8 | 1,748.3 | 79.1 | (10.3) | (0.22) | 46.9% | 4.5% | NM | 1.5 x | 32.1 x | NM |
| NextGen Healthcare, Inc. | NasdaqGS:NGXN | 16.45 | 65.4 | 1,075.5 | 31.4 | 1,107.0 | 527.8 | 38.3 | 24.2 | 0.24 | 58.4% | 7.2% | 4.6% | 2.1 x | 28.9 x | 45.7 x |
| Medidata Solutions, Inc. | NasdaqGS:MDSO | 91.20 | 60.3 | 5,495.0 | (13.2) | 5,481.8 | 684.6 | 71.6 | 31.7 | 0.46 | 73.6% | 10.5% | 4.6% | 8.0 x | 76.6 x | 172.9 x |
| Veeva Systems Inc. | NYSE:VEEV | 170.64 | 147.3 | 25,129.4 | (1,310.4) | 23,819.0 | 911.4 | 266.0 | 250.1 | 1.02 | 72.5% | 29.2% | 27.4% | 26.1 x | 89.5 x | 95.2 x |
| Median | | \$74.5 | \$106.3 | \$4,307.2 | \$37.9 | \$4,322.8 | \$873.7 | \$93.5 | \$49.8 | \$0.49 | 63.6% | 14.3% | 11.7% | 4.1 x | 30.7 x | 46.6 x |
| Increase from Week Prior | | \$3.8 | \$0.0 | \$157.8 | \$0.0 | \$157.8 | \$0.0 | \$0.0 | \$0.0 | \$0.0 | 0.0% | 0.0% | 0.0% | 0.2 x | -2.8 x | -7.6 x |
| Increase from Year to Date | | \$44.2 | \$6.7 | \$1,171.7 | (\$14,116.1) | (\$12,851.2) | (\$17,760.3) | (\$2,104.5) | (\$1,351.2) | (\$1.4) | 24.7% | 0.0% | 0.0% | 3.1 x | 22.9 x | 34.3 x |
| Increase from Year over Year | | \$16.9 | \$2.5 | \$903.5 | \$41.1 | \$176.4 | \$131.6 | \$12.3 | \$4.1 | \$0.1 | 0.2% | 0.0% | 0.0% | 0.7 x | -10.5 x | -20.7 x |

\$ in millions, except for per-share amounts

All Data as of: 7/26/2019

Healthcare Distributors

| Company | Ticker | Share Price | Shares Out | Equity Value | Net Debt (Cash) | Enterprise Value | LTM | | | Margin Analysis | | | Enterprise Value/ | | | |
|-------------------------------|---------------|-------------|------------|--------------|-----------------|------------------|-------------|-------------|-------------|-----------------|--------------|--------|-------------------|--------|--------|--------|
| | | | | | | | Sales | EBITDA | EBIT | EPS | Gross Profit | EBITDA | EBIT | Sales | EBITDA | EBIT |
| McKesson Corporation | NYSE:MCK | \$138.61 | 186.4 | \$25,833.7 | \$4,665.0 | \$30,498.7 | \$214,319.0 | \$4,229.0 | \$3,280.0 | \$8.62 | 5.5% | 2.0% | 1.5% | 0.1 x | 7.2 x | 9.3 x |
| Cardinal Health, Inc. | NYSE:CAH | 45.15 | 298.1 | 13,457.4 | \$5,642.0 | 19,099.4 | 143,530.0 | 2,775.0 | 1,763.0 | 3.25 | 4.8% | 1.9% | 1.2% | 0.1 x | 6.9 x | 10.8 x |
| AmerisourceBergen Corporation | NYSE:ABC | 86.01 | 210.2 | 18,076.3 | 1,767.1 | 19,843.4 | 175,151.5 | 2,276.4 | 1,735.6 | 4.44 | 2.7% | 1.3% | 1.0% | 0.1 x | 8.7 x | NM |
| Owens & Minor, Inc. | NYSE:OMI | 2.75 | 62.9 | 172.8 | 1,873.5 | 2,046.2 | 9,927.5 | 217.4 | 117.4 | 0.62 | 14.4% | 2.2% | 1.2% | 0.2 x | 9.4 x | 17.4 x |
| Henry Schein, Inc. | NasdaqGS:HSIC | 67.56 | 149.1 | 10,071.5 | 1,450.2 | 11,521.7 | 13,288.8 | 1,117.5 | 905.4 | 3.34 | 27.3% | 8.4% | 6.8% | 0.9 x | 10.3 x | 12.7 x |
| Patterson Companies, Inc. | Nasdaq:PDCO | 19.49 | 93.5 | 1,821.9 | 656.9 | 2,478.7 | 5,574.5 | 256.4 | 173.6 | 0.91 | 21.4% | 4.6% | 3.1% | 0.4 x | 9.7 x | 14.3 x |
| Median | | \$56.4 | \$167.7 | \$11,764.4 | \$1,820.3 | \$15,310.5 | \$78,409.4 | \$1,697.0 | \$1,320.5 | \$3.30 | 12.7% | 3.4% | 2.5% | 0.2 x | 9.1 x | 12.7 x |
| Increase from Week Prior | | \$0.1 | \$0.0 | \$28.3 | \$0.0 | \$28.3 | \$0.0 | \$0.0 | \$0.0 | \$0.0 | 0.0% | 0.0% | 0.0% | 0.0 x | 0.0 x | 0.0 x |
| Increase from Year to Date | | (\$83.1) | (\$89.9) | (\$24,639.2) | (\$1,380.7) | (\$25,585.1) | \$24,120.4 | (\$2,327.0) | (\$2,401.5) | (\$5.2) | -10.7% | 0.0% | 0.0% | -0.5 x | -1.1 x | 1.7 x |
| Increase from Year over Year | | (\$6.8) | (\$9.2) | (\$1,830.8) | (\$400.9) | (\$1,998.8) | \$3,965.3 | (\$13.6) | (\$55.6) | \$0.2 | -0.1% | 0.0% | 0.0% | 0.0 x | -0.4 x | -0.1 x |

Healthcare Supplies

| Company | Ticker | Share Price | Shares Out | Equity Value | Net Debt (Cash) | Enterprise Value | LTM | | | Margin Analysis | | | Enterprise Value/ | | | |
|------------------------------------|---------------|-------------|------------|--------------|-----------------|------------------|-----------|---------|---------|-----------------|--------------|--------|-------------------|-------|--------|--------|
| | | | | | | | Sales | EBITDA | EBIT | EPS | Gross Profit | EBITDA | EBIT | Sales | EBITDA | EBIT |
| Teleflex Incorporated | NYSE:TFX | \$346.52 | 46.2 | \$15,993.3 | \$1,989.9 | \$17,983.3 | \$2,474.7 | \$672.0 | \$492.6 | \$5.28 | 58.0% | 27.2% | 19.9% | 7.3 x | 26.8 x | 36.5 x |
| Haemonetics Corporation | NYSE:HAE | 123.60 | 51.3 | 6,335.8 | 180.8 | 6,516.6 | 967.6 | 188.5 | 104.7 | 1.15 | 45.3% | 19.5% | 10.8% | 6.7 x | 34.6 x | 62.2 x |
| West Pharmaceutical Services, Inc. | NYSE:WST | 137.63 | 73.5 | 10,113.7 | 7.6 | 10,121.3 | 1,767.4 | 391.9 | 288.4 | 2.17 | 32.4% | 22.2% | 16.3% | 5.7 x | 25.8 x | NM |
| Ansell Limited | ASX:ANN | 19.11 | 132.3 | 2,528.6 | 131.7 | 2,660.3 | 1,492.9 | 240.8 | 207.6 | 0.77 | 39.2% | 16.1% | 13.9% | 1.8 x | 11.0 x | 12.8 x |
| ICU Medical, Inc. | NasdaqGS:ICUI | 254.70 | 20.6 | 5,250.5 | (275.9) | 4,974.6 | 1,358.9 | 263.0 | 187.5 | 5.94 | 40.9% | 19.4% | 13.8% | 3.7 x | 18.9 x | 26.5 x |
| Coloplast A/S | CPSE:COLO B | 116.94 | 212.0 | 24,793.6 | 309.7 | 25,103.3 | 2,583.1 | 900.3 | 811.0 | 2.32 | 67.7% | 34.9% | 31.4% | 9.7 x | 27.9 x | 31.0 x |
| Median | | \$130.6 | \$62.4 | \$8,224.8 | \$156.2 | \$8,319.0 | \$1,630.2 | \$327.4 | \$248.0 | \$2.25 | 47.3% | 23.2% | 17.7% | 6.2 x | 26.3 x | 31.0 x |
| Increase from Week Prior | | \$8.9 | \$0.0 | \$638.3 | \$0.0 | \$638.3 | \$0.0 | \$0.0 | \$0.0 | \$0.0 | 0.0% | 0.0% | 0.0% | 0.4 x | 1.9 x | -0.8 x |
| Increase from Year to Date | | \$100.7 | (\$34.6) | \$5,406.7 | \$207.4 | \$5,256.6 | \$1,141.4 | \$247.7 | \$201.8 | \$1.9 | -16.1% | 0.1% | 0.1% | 2.5 x | 2.1 x | 6.6 x |
| Increase from Year over Year | | \$20.0 | (\$0.5) | \$1,115.9 | \$92.9 | \$1,388.4 | \$46.8 | (\$4.6) | \$3.2 | \$0.1 | 0.0% | 0.0% | 0.0% | 0.9 x | 2.3 x | 0.8 x |

Home Health Services

| Company | Ticker | Share Price | Shares Out | Equity Value | Net Debt (Cash) | Enterprise Value | LTM | | | Margin Analysis | | | Enterprise Value/ | | | |
|------------------------------|---------------|-------------|------------|--------------|-----------------|------------------|--------------|-------------|-----------|-----------------|--------------|--------|-------------------|-------|--------|--------|
| | | | | | | | Sales | EBITDA | EBIT | EPS | Gross Profit | EBITDA | EBIT | Sales | EBITDA | EBIT |
| Genesis Healthcare, Inc. | NYSE:GEN | 1.19 | 105.3 | 125.3 | 4,468.4 | 4,993.7 | 4,837.2 | 376.2 | 162.1 | (0.18) | 44.3% | 7.8% | 3.4% | 0.9 x | 12.2 x | 28.3 x |
| Amedisys, Inc. | NasdaqGS:AMED | 135.12 | 32.0 | 4,329.7 | 380.6 | 4,710.3 | 1,730.7 | 176.0 | 163.5 | 2.99 | 40.5% | 10.2% | 9.4% | 2.7 x | 26.8 x | NM |
| LHC Group, Inc. | NasdaqGS:LHCG | 124.13 | 31.5 | 3,909.2 | 286.9 | 4,196.2 | 2,021.5 | 191.6 | 174.3 | 2.59 | 36.2% | 9.5% | 8.6% | 2.1 x | 21.9 x | 24.1 x |
| Addus HomeCare Corporation | NasdaqGS:ADUS | 80.32 | 13.0 | 1,046.5 | (32.0) | 1,014.6 | 547.6 | 41.0 | 32.1 | 1.46 | 27.0% | 7.5% | 5.9% | 1.9 x | 24.8 x | 31.6 x |
| Median | | \$102.2 | \$31.8 | \$2,477.9 | \$333.7 | \$4,394.9 | \$1,876.1 | \$183.8 | \$162.8 | \$2.03 | 37.0% | 8.7% | 6.8% | 2.0 x | 23.3 x | 28.3 x |
| Increase from Week Prior | | \$2.4 | \$0.0 | \$43.4 | \$0.0 | \$80.0 | \$0.0 | \$0.0 | \$0.0 | \$0.0 | 0.0% | 0.0% | 0.0% | 0.1 x | 0.7 x | 0.5 x |
| Increase from Year to Date | | \$18.0 | (\$154.0) | (\$14,744.2) | (\$1,784.9) | (\$14,957.8) | (\$59,650.3) | (\$1,105.3) | (\$902.7) | (\$0.3) | 23.6% | 0.0% | 0.0% | 1.7 x | 10.6 x | 14.2 x |
| Increase from Year over Year | | \$24.1 | (\$0.5) | \$628.2 | \$164.6 | \$1,238.1 | \$409.2 | \$62.7 | \$56.4 | \$0.3 | 0.9% | 0.0% | 0.0% | 0.1 x | 2.0 x | -1.5 x |

Hospital & Emergency Services

| Company | Ticker | Share Price | Shares Out | Equity Value | Net Debt (Cash) | Enterprise Value | LTM | | | Margin Analysis | | | Enterprise Value/ | | | |
|-------------------------------------|----------|-------------|------------|--------------|-----------------|------------------|------------|-----------|-----------|-----------------|--------------|--------|-------------------|--------|--------|--------|
| | | | | | | | Sales | EBITDA | EBIT | EPS | Gross Profit | EBITDA | EBIT | Sales | EBITDA | EBIT |
| DeVita Inc. | NYSE:DVA | \$59.48 | 160.3 | \$9,532.2 | \$12,993.6 | \$22,525.8 | \$11,299.8 | \$2,054.9 | \$1,458.5 | \$2.67 | 28.1% | 18.2% | 2.0 x | 11.0 x | 15.4 x | |
| Select Medical Holdings Corporation | NYSE:SEH | 16.73 | 135.4 | 2,265.5 | 4,219.9 | 6,485.4 | 5,152.9 | 627.4 | 420.4 | 0.87 | 19.7% | 12.2% | 8.2% | 1.3 x | 10.3 x | 15.4 x |
| Encompass Health Corporation | NYSE:EHC | 67.43 | 98.9 | 6,665.6 | 2,796.3 | 9,461.9 | 4,355.3 | 906.3 | 700.0 | 2.63 | 41.1% | 20.8% | 16.1% | 2.2 x | 10.4 x | 13.5 x |
| WEDNAX, Inc. | NYSE:MD | 23.90 | 85.2 | 2,036.9 | 2,102.9 | 4,139.8 | 3,645.7 | 539.6 | 428.2 | 2.53 | 27.8% | 14.8% | 11.7% | 1.1 x | 7.7 x | 9.7 x |
| Median | | \$41.7 | \$117.1 | \$4,465.6 | \$3,908.1 | \$7,973.7 | \$4,754.1 | \$766.8 | \$564.1 | \$2.58 | 29.2% | 16.5% | 12.2% | 1.6 x | 10.4 x | 14.5 x |
| Increase from Week Prior | | \$1.8 | \$0.0 | \$137.6 | \$0.0 | \$137.6 | \$0.0 | \$0.0 | \$0.0 | \$0.0 | 0.0% | 0.0% | 0.0% | 0.2 x | 0.2 x | 0.2 x |
| Increase from Year to Date | | (\$29.0) | \$55.7 | \$1,112.6 | \$3,334.4 | \$4,364.3 | \$3,262.9 | \$520.7 | \$378.2 | \$1.1 | -20.2% | -0.1% | -0.1% | -1.7 x | -4.0 x | -4.4 x |
| Increase from Year over Year | | (\$15.0) | \$0.7 | (\$1,276.4) | \$572.9 | (\$135.9) | \$339.3 | \$45.0 | (\$14.6) | (\$0.1) | -0.4% | 0.0% | 0.0% | -0.2 x | -0.2 x | 0.5 x |

\$ in millions, except for per-share amounts

All Data as of: 7/26/2019

Healthcare Industry Averages

| Subsector | Ticker | Share Price | Shares Out | Equity Value | Net Debt (Cash) | Enterprise Value | LTM | | | | Margin Analysis | | | Enterprise Value/ | | |
|-------------------------------|--------|-------------|------------|--------------|-----------------|------------------|------------|------------|------------|--------|-----------------|--------|-------|-------------------|--------|---------|
| | | | | | | | Sales | EBITDA | EBIT | EPS | Gross Profit | EBITDA | EBIT | Sales | EBITDA | EBIT |
| Diversified Pharmaceuticals | N/A | \$75.79 | 3,222.2 | \$204,134.2 | \$23,116.3 | \$227,250.5 | \$49,252.5 | \$16,889.7 | \$12,030.7 | \$2.38 | 72.2% | 33.0% | 22.8% | 4.7 x | 15.3 x | 28.4 x |
| Specialty Pharmaceuticals | N/A | 58.48 | 447.1 | 22,929.3 | 15,560.9 | 38,490.2 | 8,593.9 | 2,970.0 | 956.7 | (1.32) | 75.4% | 36.4% | 12.7% | 3.8 x | 11.1 x | 416.1 x |
| Generic Pharmaceuticals | N/A | 25.49 | 434.1 | 7,038.1 | 7,445.4 | 14,483.4 | 6,787.8 | 1,708.3 | 959.3 | 1.16 | 50.2% | 22.9% | 13.9% | 2.4 x | 11.0 x | 18.1 x |
| Nutraceuticals | N/A | 48.61 | 42.0 | 1,819.3 | 212.6 | 2,032.0 | 1,434.5 | 214.7 | 188.6 | 2.32 | 73.8% | 11.3% | 9.8% | 1.2 x | 10.7 x | 13.1 x |
| Biotechnology | N/A | 129.46 | 932.6 | 81,167.2 | 4,129.3 | 85,296.5 | 16,891.9 | 8,153.6 | 7,234.4 | 6.97 | 79.8% | 47.0% | 42.0% | 5.2 x | 12.5 x | 15.5 x |
| Medical Devices | N/A | 126.90 | 816.6 | 65,736.0 | 9,115.8 | 74,851.8 | 13,307.6 | 3,902.5 | 2,640.4 | 2.49 | 67.6% | 28.9% | 20.7% | 6.5 x | 22.2 x | 30.8 x |
| Healthcare Facilities | N/A | 64.24 | 136.1 | 13,129.6 | 14,247.1 | 27,376.7 | 18,533.9 | 3,062.5 | 2,219.7 | 2.90 | 38.0% | 13.1% | 9.0% | 1.2 x | 10.0 x | 16.7 x |
| Managed Care | N/A | 209.21 | 426.9 | 87,635.7 | 17,010.2 | 104,645.9 | 106,398.8 | 8,124.2 | 7,234.4 | 9.95 | 21.0% | 7.1% | 6.2% | 0.9 x | 12.1 x | 13.7 x |
| Healthcare Services | N/A | 144.59 | 149.2 | 22,545.1 | 10,068.4 | 32,613.5 | 19,833.5 | 2,316.0 | 1,861.5 | 6.18 | 33.4% | 18.6% | 13.7% | 2.8 x | 14.8 x | 20.1 x |
| Healthcare Technology | N/A | 72.99 | 134.3 | 10,077.6 | (42.0) | 10,035.6 | 1,705.8 | 294.4 | 186.8 | 0.59 | 63.6% | 14.3% | 11.7% | 7.6 x | 46.1 x | 78.4 x |
| Healthcare Distributors | N/A | 59.93 | 166.7 | 11,572.2 | 2,675.8 | 14,248.0 | 9,631.9 | 1,811.9 | 1,329.2 | 3.53 | 12.7% | 3.4% | 2.5% | 0.3 x | 8.7 x | 12.9 x |
| Healthcare Supplies | N/A | 166.42 | 89.3 | 10,835.9 | 390.6 | 11,226.6 | 1,774.1 | 442.7 | 348.6 | 2.94 | 47.3% | 23.2% | 17.7% | 5.8 x | 24.2 x | 33.8 x |
| Home Health Services | N/A | 85.19 | 45.5 | 2,352.7 | 1,276.0 | 3,628.7 | 2,284.2 | 196.2 | 133.0 | 1.71 | 37.0% | 8.7% | 6.8% | 1.9 x | 21.4 x | 28.0 x |
| Hospital & Emergency Services | N/A | 41.89 | 119.9 | 5,125.1 | 5,528.2 | 10,653.2 | 6,113.4 | 1,032.0 | 751.8 | 2.18 | 29.2% | 16.5% | 12.2% | 1.6 x | 9.9 x | 13.5 x |
| Median | | \$74.4 | \$157.9 | \$12,350.9 | \$6,486.8 | \$20,930.1 | \$10,950.8 | \$2,064.0 | \$1,144.2 | \$2.43 | 50.1% | 20.3% | 14.4% | 2.6 x | 12.3 x | 19.1 x |
| Increase from Week Prior | | \$0.9 | \$0.0 | \$381.7 | \$0.0 | \$425.4 | \$0.0 | \$0.0 | \$0.0 | \$0.0 | 0.0% | 0.0% | 0.0% | 0.0 x | -0.1 x | 0.6 x |
| Increase from Year to Date | | \$8.7 | (\$5.3) | (\$4,364.4) | \$3,991.9 | (\$1,041.1) | \$2,029.1 | \$194.3 | (\$236.7) | \$0.2 | -1.4% | 0.0% | 0.0% | -0.5 x | -1.9 x | -1.6 x |
| Increase from Year over Year | | \$2.2 | \$2.5 | \$205.0 | \$1,965.2 | \$660.8 | \$572.6 | \$159.8 | (\$84.4) | \$0.2 | 0.0% | 0.0% | 0.0% | -0.1 x | -1.7 x | -4.5 x |